Nama's AI scorecard currently rates Amgen Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AMGN's P/E ratio?

Amgen trades at a trailing price-to-earnings ratio of 19.9.

When does AMGN report earnings?

Amgen's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $5.76.

What is the AMGN price target?

The median analyst price target from 29 analysts is $415.00, with a range of $225.00 – $536.00.

Is AMGN Shariah compliant?

Nama's AAOIFI-style screen reads Amgen as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does AMGN pay a dividend?

Yes — Amgen's dividend yield is 2.2%.

Nama Insights

Amgen (AMGN)

Healthcare · Drug Manufacturers General · NASDAQ

S&P 500Nasdaq-100

Amgen (AMGN) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $249.05B, a trailing price-to-earnings ratio of 19.9 and a free-cash-flow yield of 3.2%. Over the most recent reported fiscal year, revenue grew 9.9% and free cash flow per share fell 22.2%. Nama's AI scorecard rates it Buy, 6.9 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +30.9% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-4.9%

How far the last close sits under the highest price of the past five years.

Market cap	$249.05B
Trailing P/E	19.9
Price / book	21.3
Price / sales	6.5
FCF yield	3.2%
Dividend yield	2.2%
Gross margin	69.5%
Operating margin	30.0%
Net margin	22.9%
Revenue growth (YoY)	+9.9%
Revenue growth (3-yr annual)	+11.8%
EPS growth (YoY)	+10.2%
FCF/share growth (YoY)	-22.2%
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers General

AMGN earnings

Next report: Feb 2, 2027 (Q4 2026, EPS estimate $5.76). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$6.45	$5.78	+11.6%	$10.37B
Q2 2026	Aug 4, 2026	$6.29	$5.62	+11.9%	$10.05B
Q1 2026	Apr 30, 2026	$5.15	$4.77	+8.0%	$8.62B
Q4 2025	Feb 3, 2026	$5.29	$4.73	+11.8%	$9.87B

AMGN analyst price target

Median target $415.00 from 29 analysts, ranging $225.00 – $536.00.

Drug Manufacturers General peers

Ticker	Company	Market cap	P/E
LLY	Eli Lilly	$1.21T	42.4
JNJ	Johnson & Johnson	$664.95B	25.9
ABBV	AbbVie	$514.92B	22.7
MRK	Merck	$361.73B	47.0
NVS	Novartis	$307.00B	19.0
AZN	AstraZeneca	$289.14B	38.8
GILD	Gilead Sciences	$207.00B	—
NVO	Novo Nordisk A/S	$177.74B	11.0

Explore live AMGN data on Nama Insights →

Recent Congressional trades

Amgen trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
David J. Taylor	House	Buy	$1,001 - $15,000	Oct 1, 2026
David J. Taylor	House	Sell	$1,001 - $15,000	Sep 5, 2026
Sheldon Whitehouse	Senate	Sell	$1,001 - $15,000	Sep 2, 2026
Thomas H Tuberville	Senate	Sell	$15,001 - $50,000	Aug 5, 2026
Alan Armstrong	Senate	Sell	$15,001 - $50,000	Jul 21, 2026
Maria Elvira Salazar	House	Sell	$15,001 - $50,000	May 8, 2026
Maria Elvira Salazar	House	Buy	$15,001 - $50,000	Apr 21, 2026
David J. Taylor	House	Sell	$1,001 - $15,000	Feb 2, 2026
Julia Letlow	House	Sell	$1,001 - $15,000	Jan 13, 2026
David J. Taylor	House	Sell	$1,001 - $15,000	Dec 5, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Oct 22, 2025
Daniel Meuser	House	Sell	$1,001 - $15,000	Aug 20, 2025

AMGN FAQ

Is AMGN a buy?: Nama's AI scorecard currently rates Amgen Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AMGN's P/E ratio?: Amgen trades at a trailing price-to-earnings ratio of 19.9.
When does AMGN report earnings?: Amgen's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $5.76.
What is the AMGN price target?: The median analyst price target from 29 analysts is $415.00, with a range of $225.00 – $536.00.
Is AMGN Shariah compliant?: Nama's AAOIFI-style screen reads Amgen as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does AMGN pay a dividend?: Yes — Amgen's dividend yield is 2.2%.